EFFECT OF ANTI-OESTROGEN TAMOXIFEN ON PLASMA-LEVELS OF LUTEINIZING-HORMONE, FOLLICLE-STIMULATING-HORMONE, PROLACTIN, ESTRADIOL AND PROGESTERONE IN NORMAL PREMENOPAUSAL WOMEN
EFFECT OF ANTI-OESTROGEN TAMOXIFEN ON PLASMA-LEVELS OF LUTEINIZING-HORMONE, FOLLICLE-STIMULATING-HORMONE, PROLACTIN, ESTRADIOL AND PROGESTERONE IN NORMAL PREMENOPAUSAL WOMEN
复制标题
DOI:
10.1677/joe.0.0700421
复制
发表时间:
1976-01-01
影响因子:
4
通讯作者:
GRIFFITHS, K
中科院分区:
文献类型:
--
作者:
GROOM, GV;GRIFFITHS, K
Plasma levels of LH [luteinizing hormone], FSH [follicle-stimulating hormone], prolactin, estradiol and progesterone were determined daily during 2 menstrual cycles in 6 women volunteers. During the 1st (control) cycle no treatment was given and normal secretion of these hormones was observed. Oral administration of tamoxifen (20 mg/day), for 5 or 10 days of the follicular phase of the 2nd cycle, caused no change in the overall length of the cycle or the time of occurrence of the midcycle gonadotropin surge. There was little difference in the secretion of LH, FSH and progesterone during the control and test cycles. A 2- to 8-fold increase in estradiol levels was observed during the test cycle which was most pronounced at the times of midcycle and midluteal hormone peaks. There was a significant decrease in plasma prolactin levels at midcycle, but no real difference could be seen during the remainder of the cycle. Tamoxifen may act directly on the ovary to stimulate estradiol release without intermediary gonadotropin stimulation. As the drug apparently inhibited prolactin secretion even in the presence of high estradiol levels, an alternative explanation may be that the reduced prolactin concentration permits augmented ovarian stimulation by normal concentrations of gonadotropins. [This study shows a mechanism of action for tamoxifen in breast cancer treatment.].